Daniel D. Karp

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Table S1 from Discordance of HER2 Expression and/or Amplification on Repeat TestingPreprint

  2025-11-27

• Table S2 from Discordance of HER2 Expression and/or Amplification on Repeat TestingPreprint

  2025-11-27

• Supplementary Tables S1-S4 from Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

  2025-11-25

• Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

  2025-11-25

• Supplementary Table S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

  2025-11-25

• Supplementary Table S3 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors

  2025-09-15

• Supplementary Table S1 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors

  2025-09-15

• Data from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors

  2025-09-15

• Supplementary Table S2 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors

  2025-09-15

• Supplementary Table S4 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors

  2025-09-15

• Supplementary Figure S1 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid TumorsPreprint

  2025-09-15

• Supplementary Figure S2 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid TumorsPreprint

  2025-09-15

• Supplementary File S1 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors

  2025-09-15

• Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i> -NT in Patients with Advanced Solid Tumors

  Clinical Cancer Research · 2025-07-11 · 7 citations

• Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancers

  Med · 2025-06-27 · 1 citations

• EphA2 siRNA in DOPC nanoliposomes (EPHARNA): A phase I clinical trial in patients with solid tumors.

  Journal of Clinical Oncology · 2025-05-28

• Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study

  Investigational New Drugs · 2025-02-20

• Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial

  Journal of Immunotherapy and Precision Oncology · 2025-02-06 · 3 citations

• A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma

  Cancer Medicine · 2025-02-01 · 3 citations

• A phase 2 basket study of talabostat, a small‐molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers

  Cancer · 2025-01-23 · 4 citations